| Print Friendly |
| Thursday, September 23, 2004 |
| |
| 8:00 a.m. |
Welcome
William S. Loiry
President & Host
Equity International |
| |
| |
Top government officials discuss BioDefense programs and opportunities. |
| |
 |
Dr. Diane Berry- Moderator
Senior Advisor
McKenna Long & Aldridge |
| |
 |
| |
|
Joseph T. Bielitzki, MS,
DVM
Program Manager
Defense Advanced Research Projects Agency
|
| |
|
| |
|
Colonel Stephen B. Berté, Ph.D.
Joint Project Manager
Chemical Biological Medical Systems
United States Army
|
| |
|
| |
|
Boris D. Lushniak
Chief Medical Officer,
Office of Counter-terrorism Policy
Food and Drug Administration
|
|
| |
|
| 9:00 a.m. |
NETWORKING BREAK |
| |
| 9:15 a.m. |
BioShield and BioShield II |
| |
Congressional staff members discuss the history of BioShield and possibilities for BioShield II. |
|
Frank Rapoport -Moderator
Partner
McKenna Long & Aldridge
|
|
|
Chuck Ludlam
Counsel
Office of Senator Joseph Lieberman
|
|
|
Steve Irizarry
Counsel
U.S. Senate Committee on Health,
Education,
Labor and Pensions
|
|
| |
|
Russ Caso
Counsel
Office of Congressman Curt Weldon |
|
| |
| 10:05 a.m. |
Industry Perspective on BioDefense |
| |
Pharmaceutical companies discuss trends and developments in the BioDefense industry. |
|
Christopher Bouquet -Moderator
Associate
McKenna Long & Aldridge
|
|
Dan Jacobs
Chairman/CEO
The Federal Market Group
|
|
Gregory J. Davenport, Ph.D.
President, Biodefense Division
DOR BioPharma, Inc. |
|
George Painter
President/CEO
Chimerix, Inc.
|
|
| |
|
| 11:00 a.m. |
Adjournment |
| |
|
| |
*Final Program Subject to Change |
